ArticleJournal of virology2003
Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods.
Article in Journal of virology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 232 citations in OpenAlex.
- Aviadenovirus structure: A highly thermostable capsid in the absence of stabilizing proteins.PLoS pathogens · 2025Article
- Molecular characterization and evolutionary analysis of human adenovirus type 55, related to febrile respiratory illness in the South Korean military.Virus genes · 2025Article
- Hybrid sequencing reveals the genome of a Chrysochromulina parva virus and highlight its distinct replication strategy.BMC genomics · 2025Article
- Molecular mechanisms of the viral encoded chaperone 100K in capsid folding and assembly of adenovirus.Nature communications · 2025Article
- Seasonal dynamics and genetic diversity of human adenoviruses in patients with acute respiratory infection in Thailand, 2024.PloS one · 2025Article
- Genetic Evidence of Active Circulation and Evolution of Diverse Penguin Siadenoviruses in Antarctica Based on Partial DNA Sequences.Transboundary and emerging diseases · 2025Article
- Review
- Differences in the pathogenicity and molecular characteristics of fowl adenovirus serotype 4 epidemic strains in Guangxi Province, southern China.Frontiers in microbiology · 2024Article
- Conflicting Evidence between Clinical Perception and Molecular Epidemiology: The Case of Fowl Adenovirus D.Animals : an open access journal from MDPI · 2023Article
- Prevalence and Molecular Characteristics of FAdV-4 from Indigenous Chicken Breeds in Yunnan Province, Southwestern China.Microorganisms · 2023Article
- Structural Framework for Analysis of CD4+ T-Cell Epitope Dominance in Viral Fusion Proteins.Biochemistry · 2023Review
- Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity.Vaccines · 2023Article
- Pathogenicity and molecular characteristics of fowl adenovirus serotype 4 with moderate virulence in Guangxi Province, China.Frontiers in veterinary science · 2023Article
- Noninvasive Surveillance and Evolutionary Insight into Siadenovirus among Antarctic Penguins.Transboundary and emerging diseases · 2023Article
- SpeciesViruses · 2022Article
- Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform.Nano research · 2022Review
- Human Adenovirus Associated Hepatic Injury.Frontiers in public health · 2022Review
- Epidemiological and molecular analysis of circulating fowl adenoviruses and emerging of serotypes 1, 3, and 8b in Egypt.Heliyon · 2021Article
- Construction and Characterization of a Novel Recombinant Attenuated and Replication-Deficient Candidate Human Adenovirus Type 3 Vaccine: "Adenovirus Vaccine Within an Adenovirus Vector".Virologica Sinica · 2021Article
- Near-atomic structure of an atadenovirus reveals a conserved capsid-binding motif and intergenera variations in cementing proteins.Science advances · 2021Article
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
A major impediment to the use of adenovirus as a gene therapy vector and for vaccine applications is the host immune response to adenovirus hexon-the major protein component of the icosahedral capsid. A solution may lie in novel vectors with modified or chimeric hexons designed to evade the immune response. To facilitate this approach, we have distinguished the portion of hexon that all serotypes have in common from the hypervariable regions that are responsible for capsid diversity and type-specific immunogenicity. The common hexon core-conserved because it forms the viral capsid-sets boundaries to the regions where modifications can be made to produce nonnative hexons. The core has been defined from the large and diverse set of known hexon sequences by an accurate alignment based on the newly refined crystal structures of human adenovirus types 2 (Ad2) and Ad5 hexon. Comparison of the two hexon models, which are the most accurate so far, reveals that over 90% of the residues in each have three-dimensional positions that closely match. Structures for more distant hexons were predicted by building molecular models of human Ad4, chimpanzee adenovirus (AdC68), and fowl adenovirus 1 (FAV1 or CELO). The five structures were then used to guide the alignment of the 40 full-length (>900 residues) hexon sequences in public databases. Distance- and parsimony-based phylogenetic trees are consistent and reveal evolutionary relationships between adenovirus types that parallel those of their animal hosts. The combination of crystallography, molecular modeling, and phylogenetic analysis defines a conserved molecular core that can serve as the armature for the directed design of novel hexons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.